DRUG — BRIGHT MINDS BIOSCIENCES INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1827401 ·
Last close
$51.80
Market Cap
$508.26M
52W High
$123.75
52W Low
$48.94
ADV30
107,820
Next earnings
2026-08-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -11,434,277 | -2,398,255 | 310,336,533 | 307,828,515 | 2,543,873 |
| Mar 2026 | 0 | — | -15,319,423 | -10,459,627 | 312,365,111 | 309,691,863 | 3,832,687 |
| Dec 2025 | 0 | — | -6,904,082 | -7,565,318 | 90,879,853 | 89,047,867 | 1,599,304 |
| Sep 2025 | 0 | — | -5,664,542 | -4,085,603 | 84,421,539 | 82,908,589 | 2,376,616 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,833,944
Investing CF
—
Financing CF
$275,158,777
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-64,603,262
Inventory
—
Receivables
$1,139,911
ST Investments
—
EBIT TTM
$-31,184,357
Pretax Income TTM
$-27,353,518
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -13,937,584 | -12,229,348 | 84,421,539 | 2,376,616 | 82,044,923 | -8,691,619 |
| Sep 2024 | 0 | -2,822,767 | -2,801,946 | 6,104,602 | 568,259 | 5,536,343 | -1,850,186 |
| Sep 2023 | 0 | -7,386,414 | -7,372,225 | 6,879,072 | 280,856 | 6,598,216 | -7,024,265 |
| Sep 2022 | 0 | -14,975,092 | -14,964,941 | 12,086,984 | 1,544,472 | 10,542,512 | -13,587,116 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.89
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $55.00 · spot: $51.80 · call volume: 6 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | $504.33M | $9.77 | — |
| INDP | Indaptus Therapeutics, Inc. | $512.98M | $3.85 | — |
| KMDA | KAMADA LTD | $503.23M | $8.72 | — |
| OCS | Oculis Holding AG | $514.74M | $9.27 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $519.64M | $13.99 | — |
News headlines (Yahoo Finance, 1h cache)
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
2026-08-27 16:00 · Yahoo
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
2026-08-26 13:55 · Yahoo
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
2026-07-23 13:55 · Yahoo
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
2026-07-22 16:00 · Yahoo
3 Small Cap Stocks With Strong Revenue Growth And Low Debt
2026-09-16 00:46 · Yahoo
Bright Minds Biosciences to Present at Upcoming Conferences
2026-09-04 20:30 · Yahoo
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
2026-08-10 13:55 · Yahoo
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
2026-03-06 15:15 · Yahoo
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
2026-02-19 02:31 · Yahoo
Canadian Securities Exchange Reports January 2026 Performance Figures
2026-02-17 15:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.